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Objective: We report our experience with 93 consecutive pulmonary artery reconstructions during pulmonary
lobectomy with regard to morbidity, mortality, and long-term survival.
Methods: Clinical records of all patients who underwent lobectomy with partial or circumferential pulmonary
artery resection in a single institution during an 8-year period were reviewed retrospectively.
Results: Lobectomy with partial (n¼ 90) or circumferential (n¼ 3) pulmonary artery resection was carried out in
93 patients. Indications for surgical intervention were non–small cell lung cancer in 87 patients and other malig-
nancy in the remaining 6 patients. Bronchial sleeve resection was associated in 23 patients. Neoadjuvant chemo-
therapy had been administered in 34 cases because of cN2 disease. Operative mortality was 5.4%. Postoperative
complications occurred in 27 (29.0%) patients. All the patients underwent contrast-enhanced computed tomo-
graphic scanning 6 to 8 weeks postoperatively, which always showed patency of the pulmonary arteries. In
the whole population median and 5-year survivals were 40 months and 39.4%, respectively. Disease-free survival
was 41.4% at 5 years. Among patients with non–small cell lung cancer, at univariate analysis, tumor size of less
than 3 cm; presence of vascular peritumoral emboli, intratumoral emboli, or both; and dyspnea influenced 5-year
survival. Multivariate analysis showed that the size of the primary tumor and the presence of vascular emboli were
independent factors of worse outcome.
Conclusions: Lobectomy with arterial sleeve resection has acceptable mortality and no specific complications.
Late results in terms of survival are satisfactory.Pneumonectomy has been the typical treatment for lung can-
cers with involvement of lobar bronchus, direct invasion of
the pulmonary artery (PA), or metastasis to N1 regional
lymph nodes. Because of morbidity, mortality, and reduc-
tion of quality of life,1-3 some surgeons established the bases
of parenchymal sparing resection: bronchoplasty and PA re-
construction.4,5 These techniques were also developed to al-
low resection in patients with limited pulmonary function,
contraindicating pneumonectomy.
In the past 2 decades, many authors confirmed the feasibil-
ity and efficacy of sleeve bronchial lobectomy.6-10 Neverthe-
less, for many years, PA reconstruction did not seem to be
a real alternative to pneumonectomy, and even recently, re-
sults were quite discouraging in terms of complications.11
Relatively limited experience is available on large clinical se-
ries,12 and interpretation is difficult because of the heteroge-
neity of populations and indications for surgical techniques.
The aim of this retrospective study was reporting short-
and long-term results of our experience with arterial resec-
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variate and multivariate analyses were carried out to identify
predictors of morbidity, mortality, and long-term survival.
MATERIALS AND METHODS
We retrospectively reviewed the clinical records of all the patients who
underwent lobectomy with partial or circumferential PA resection in a single
institution during an 8-year period (November 2000–March 2008) in the
Thoracic Surgery Department, Hoˆtel-Dieu University Hospital, Paris,
France. PA resection was defined as a resection that involved, at least cir-
cumferentially, the origin of a segmental artery.
For all the patients, preoperative evaluation included clinical history,
physical examination, routine blood tests, electrocardiographic analysis,
lung function tests, and perfusion lung scanning. The lung cancer staging
protocol included chest radiographic analysis, fiberoptic bronchoscopy,
and thoracic, upper abdominal, and cerebral computed tomographic (CT)
scans. Isotopic bone scanning was performed in the presence of bone
pain, abnormalities in serum calcium or alkaline phosphatase levels, or both.
In case of clinical suspicion of N2 disease (short axis>1 cm at CT scan),
mediastinal staging by means of either transbronchial needle aspiration or,
more frequently, mediastinoscopic analysis was carried out. In rare cases the
disease was staged as N2 on the basis of CT and positron emission tomo-
graphic scanning without histologic confirmation because of the presence
of bulky homolateral lymph nodes. If N2 disease was confirmed, neoadju-
vant chemotherapy was administered. Patients were then considered opera-
ble in the presence of a clinical response13,14 or stable disease. In case of
progressive disease, surgical intervention was denied.
Resection was considered functionally possible if the predictive postop-
erative forced expiratory volume in 1 second (FEV1; calculated on the basis
of spirometry and isotopic scanning) was greater than 40% of the predicted
value and provided that no major hypoxemia (<60 mm Hg) or hypercapnia
(>46 mm Hg) existed, whereas it was contraindicated if the predicted post-
operative FEV1 was less than 30%. When FEV1 values were between 30%
and 40%, patients were considered at relatively high risk, and a definitiveurgery c June 2009




CT ¼ computed tomographic
FEV1 ¼ forced expiratory volume in 1 second
PA ¼ pulmonary artery
decision was based on an evaluation including multiple parameters (predic-
tive postoperative FEV1, PO2, PCO2, carbon monoxide transfer factor, age,
associated comorbidities and results of exercise tests [ie, stair climbing
and 6-minute walking].
Operations were carried out after achievement of general anesthesia with
double-lumen endobronchial intubation. Access to the thoracic cavity was
achieved through a standard posterolateral thoracotomy. If necessary, arte-
rial sleeve resection was carried out when possible and not only in the case
of respiratory impairment contraindicating pneumonectomy. A tangential
arterial resection with direct sutures was carried out when possible (residual
arterial caliber, 50%). Otherwise, application of an autologus pericardial
patch or circumferential resection was performed. Suturing was carried out
with double continuous 5-0 polypropylene sutures. Just before tying, the
clamp was removed.
Margins were checked intraoperatively by using frozen sections. Full
nodal dissection was carried out in all cases. If bronchial and arterial suture
lines were in close proximity to each other and in every case of associated
bronchoplasty, a pedicled flap (pleural and, much more frequently, intercos-
tal muscle) was interposed between the 2 structures.
We did not usually administer heparin sodium during the operation, but
each patient received perioperative antithrombotic prophylaxis with low-
molecular-weight heparin at preventive doses.
Pain control was achieved in most cases by means of intrathecal mor-
phine administration (at the end of the operation), followed by continuous
patient-controlled intravenous analgesia with morphinics. Intravenous prop-
aracetamol was also administered. Supplemental subcutaneous morphinics
were administered to achieve a numeric analog at a constant score (range,
1–10) of less than 4 at rest.
A policy of early extubation was systematically adopted. In the postop-
erative period a policy of high suspicion of cardiorespiratory complication
was adopted. In case of suspicion of postoperative pneumonia, a sample for
bacteriology was obtained by means of protected distal brushing before in-
stitution of any antibiotic treatment.15
All the patients underwent contrast-enhanced CT scanning 6 to 8 weeks
postoperatively. Adjuvant radiotherapy or chemotherapy was performed
under the care of referring physicians, and therefore no uniform protocol
was used.
Retrospective recording of presurgical data included demographic infor-
mation, medical comorbidities, side and location, spirometric data, and pos-
sible use of induction therapy. With respect to surgical and pathologic data,
we collected data about the extent of resection, the pathologic staging, the
completeness of resection, and postoperative morbidity and mortality. Pos-
sible postoperative treatments were also recorded.
Operative mortality was calculated by taking into account all the deaths
occurring within 30 days from the operation or during the hospitalization.
Correlation between mortality and potential risk factors was assessed by us-
ing the c2 or Fisher’s exact tests for categorical variables and the U test for
continuous variables. Factors associated with morbidity or mortality were
entered into a logistic regression analysis.
Follow-up information was obtained by means of direct telephone inter-
view with patients or, in case of deaths, with families. Referring physicians
were also contacted to confirm data obtained by means of patient or family
interviews. Overall survival rates (including non–cancer-related deaths) and
disease-free survival were calculated by using the Kaplan–Meier method
and compared with the log-rank test. All the clinical and pathologic vari-
ables with a possible effect on survival were entered in a multivariate anal-The Journal of Thoracic and Cysis (Cox proportional hazard model) to identify independent prognostic
factors.
Informed consent was obtained from all the patients or relatives (in case
of deceased patients), and investigations were conducted according to the
Declaration of Helsinki principles. The study was carried out according to
the French laws on biomedical research.
RESULTS
Between February 2001 and February 2008, 4530 major
lung resections were performed by our team: 584 pneumo-
nectomies, 3732 lobectomies, and 214 sleeve lobectomies.
Among the sleeve lobectomies, there were 121 bronchial
sleeve lobectomies, 23 bronchovascular sleeve lobectomies,
and 70 lobectomies with PA resection. These last 93 patients
represent the population of this study.
Preoperative Data
There were 70 (75.3%) men and 23 (24.7%) women;
mean age was 64.6  8.7 years. Thirty-two patients were
older than 70 years, and 87.1% were smokers. Comorbid-
ities were present in 59 (63.4%) patients, and in particular,
21.5% had a history of a previous neoplasm. Twenty pa-
tients had a history of cardiovascular disease (coronary
artery disease, n ¼ 12; arrhythmia requiring specific treat-
ment, n ¼ 6; cerebrovascular disease, n ¼ 1; obstructive
arteriopathy of the lower limbs, n ¼ 1).
Eighty-six patients presented with symptoms related to
lung tumors, whereas lung cancer was discovered on chest
radiographic analysis performed for other reasons in the re-
maining 7 patients. Of note, 21 patients had effort dyspnea
(Medical Research Council Dyspnea Scale 2).
Mean preoperative FEV1 was 83.3%  21.0%; 47
(50.5%) patients had an FEV1 of less than 80%. Induction
treatments were carried out in 34 patients (30 receiving che-
motherapy and 4 receiving chemoradiotherapy).
The main indication for preoperative induction therapy was
N2 disease (21 patients). Induction therapy was administered
because of cT4 disease (which was considered potentially re-
sectable) in 7 patients and in 4 patients in whom resectability
was in doubt. Two further patients had preoperative chemo-
therapy because of metastatic disease (isolated brain metasta-
sis treated with surgical intervention and radiotherapy).
All chemotherapy protocols were platinum based. The
associated drugs, doses, and schedules were extremely vari-
able because patients were referred by different pulmonolo-
gists and oncologists. Imaging re-evaluation after induction
therapy showed no complete response. Partial or minor re-
sponses were observed in 27 (79.4%) of 34 patients. Disease
stability was observed in 7 cases.
Surgical and Pathologic Data
Fifty-six upper left, 17 upper right, and 11 lower left lobec-
tomies and 9 bilobectomies (7 upper medium and 2 medium
lower) were carried out. PA tangential resection and directardiovascular Surgery c Volume 137, Number 6 1401
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STABLE 1. Pathologic features
Oncologic features No. % Mean Median
T size 4.19 cm 4 cm
Vascular neoplastic emboli 32 36.8
p Stage I T1 N0 M0 ¼ 4; T2 N0 M0 ¼ 13 17 19.5
II T0 N1 M0¼ 1; T1 N1 M0¼ 4; T2 N1 M0¼ 22; T3 N0 M0¼ 3 30 34.5
IIIA T1 N2 M0 ¼ 2; T2 N2 M0 ¼ 10; T3 N1 M0 ¼ 11 23 26.4
IIIB T1-2 N3 M0 ¼ 0; T3 N2-3 M0 ¼ 2; T4 N1-3 M0 ¼ 9 11 12.6
IV T1-4 N1-3 M1 ¼ 6 6 6.9suturing were performed in 88 (94.6%) patients. The repair
was accomplished with an autologous pericardial patch in
2 further patients and a circumferential resection and end-
to-end anastomosis in the remaining 3 patients. Bronchial
sleeve resection was associated in 23 patients.
Histologic examination showed 87 cases of non–small
cell lung cancer: squamous cell cancers, adenocarcinomas,
and large cell carcinomas in 46, 34, and 6 patients, respec-
tively. The remaining patient with a prechemotherapy diag-
nosis of large cell carcinoma had a pathologic complete
response. Pathologic staging is reported in Table 1.
Among the remaining 6 patients, 5 had a solitary pulmo-
nary metastasis (of colonic [n ¼ 3], breast [n ¼ 1], and thy-
roid [n¼1] cancer), and 1 had pulmonary mucosa-associated
lymphoid tissue lymphoma.
Postoperative Outcome
There were no intraoperative deaths. Postoperative mortal-
ity was 5.4% (n ¼ 5). Three deaths occurred after right
lobectomy (2 with bronchoplasty), and 2 occurred after left lo-
bectomy. Postoperative pneumonia and acute respiratory dis-
tress (with no infection identified) were responsible for 3
deaths. In 2 further patients acute myocardial infarction fol-
lowed by intractable cardiogenic shock was the cause of death.
Among evaluated factors (Tables 2 and 3), the following
were associated at univariate analysis with postoperative
death: age (P ¼ .043), cardiovascular disease (P ¼ .007),1402 The Journal of Thoracic and Cardiovascular Sprevious neoplasm (P ¼ .030), p stage (P ¼ .002), smoking
(P ¼ .020), and FEV1 (P ¼ .035). Multivariate analysis
showed that only cardiovascular disease (P ¼ .022) and
FEV1 (P ¼ .039) were independent predictors of postopera-
tive mortality. No statistical difference was found with re-
spect to possibly associated bronchoplasty or the extent of
resection (lobectomy or bilobectomy).
Other complications (not responsible for deaths) occurred
in 27 (29.0%) further patients and were in some instances
associated: postoperative pneumonia (n¼ 12), supraventric-
ular arrhythmias (n ¼ 5), persistent air leak without evident
bronchopleural fistula (n ¼ 5), respiratory failure (n ¼ 5),
atelectasia without pneumonia (n ¼ 3), acute pericarditis
(n ¼ 1), and delirium (n ¼ 1).
At univariate analysis, systemic hypertension (P ¼ .044),
a history of pulmonary embolism (P¼ .038), and cardiovas-
cular disease (P¼ .008) were associated with the occurrence
of postoperative complications, with only the latter remain-
ing significant at multivariate analysis (P ¼ .006).
Long-term Outcome
No patient was lost at follow-up. Mean and median fol-
low-ups were 28.1 and 24 months, respectively. At comple-
tion of the study (April 2008), 48 (51.6%) patients were
alive, and 45 (48.4%) were dead. For the whole population,
median survival was 40 months; 3- and 5-year overall sur-
vivals were 59.6% and 39.4%, respectively.TABLE 2. Univariate analysis in perioperative morbidity, mortality, and long-term survival with respect to pretherapeutic clinical data
Features Perioperative morbidity P value Perioperative mortality P value 5-y Survival P value
Sex .109 .361 .888
Age .088 .043 .594
Active smoker (yes/no) .267 .020 .281
Comorbidity .467 .394 .423
Previous neoplasm .574 .030 .353
COPD .187 .476 .923
Dyspnea .251 .074 .029
FEV1 .352 .035 NS
Hypertension .044 .620 .887
Pulmonary hypertension .116 .799 .359
Cardiovascular disease .008 .007 .661
Deep venous thrombosis .116 .895 .942
Pulmonary embolism .038 .846 .439
COPD, Chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second.urgery c June 2009
Alifano et al General Thoracic SurgeryTABLE 3. Univariate analyses in perioperative morbidity, mortality, and long-term survival with respect to treatment and pathologic data
Features Perioperative morbidity P value Perioperative mortality P value 5-y Survival P value
Histology .872 .546 .118
pT .514 .097 .094
T size .868 .283 .027
pN .718 .434 .995
pM .637 .747 .839
Vascular neoplastic emboli .076 .053 .006
p Stage .250 .005 .806
Neoadjuvant therapy .262 .551 .844
Adjuvant therapy   .230
Lung resection .743 .163 .426
Bronchoplasty .210 .361 .260G
T
SNo recurrence occurred among patients treated for iso-
lated pulmonary metastasis. Four patients with isolated local
recurrence of non–small cell lung cancer were managed with
completion pneumonectomy; a patient with tracheal recur-
rence was managed with laser induction chemotherapy and
tracheal resection. Twelve further patients presented with
both local (mediastinal adenopathies or multiple pulmonary
nodules) and extrathoracic recurrence and were managed by
means of chemotherapy, which was in 3 instances associated
with thoracic radiotherapy. Median time to local recurrence
was 34 months. The type of parenchymal sparing procedure
(arterial vs bronchovascular) was not associated with the rate
of local recurrence.
Twenty-five patients presented with extrathoracic recur-
rence with a median time of 42 months. These recurrences
were managed with chemotherapy, which was associated
with surgical intervention in 2 patients (isolated metachro-
nous adrenal and cerebellar metastasis).
Overall, among the late deaths (n¼ 45), 5 were due to in-
tercurrent causes (pneumonia, n ¼ 3; myocardial infarction,
n ¼ 1; small cell lung cancer, n ¼ 1), and the remaining 40
were attributable to recurrent disease.
With respect to long-term outcome, multivariate analyses
were performed only in patients with non–small cell lung
cancer (n ¼ 87/93), who had median and 5-year survivals
of 38 months and 34.9% (95% confidence interval,
22.8%–49.2%), respectively.
No difference in terms of long-term outcome was ob-
served with respect to sex, age, smoking habit, respiratory
functional parameters, and different comorbidities. Patients
with pretreatment effort dyspnea had worse outcomes com-
pared with those of the remaining patients (5-year survival of
18.7% vs 39.3%, P ¼ .029; Table 2).
A trend toward better outcome was observed in patients
with T1–2 tumors compared with T3–4 lesions (5-year sur-
vival of 37.3% vs 32.9%, P ¼ .094). Patients with tumors
of less than 3 cm had significantly better 5-year survival than
the remaining patients (47.9% vs 26.1%,P¼ .027; Figure 1).
We did not find significant differences with respect to his-
tologic type, nodal status (N0 vs Nþ,P¼ .930) or the possiblyThe Journal of Thoracic and Cassociated bronchoplasty (P¼ .260). The presence of peritu-
moral, intratumoral, or both neoplastic vascular emboli was
associated with worse 5-year survival (23.6% vs 43.1%,
P¼ .0068; Figure 2). Neither the presence of nodal metasta-
sis nor the stage of disease influenced prognosis (Table 3).
At multivariate analysis, the T factor and the presence of
vascular emboli were independent factors of worse outcome
(P ¼ .039 and .026, respectively).
DISCUSSION
In the present study we report evidence that arterial recon-
struction for lung cancer is a valuable procedure with accept-
able figures of postoperative morbidity and mortality and
satisfactory results on long-term survival.
The history of the last 50 years showed an increasing in-
terest in limited resections, more recently associated with the
FIGURE 1. Survival according to tumor size in patients with non–small
cell lung cancer. Patients with tumors smaller than 3 cm had significantly
(P ¼ .027) better 5-year survival than the remaining patients (47.9%
[95% confidence interval, 25.8%–68.0%] vs 26.1% [95% confidence
interval, 13.6%–44.2%]).ardiovascular Surgery c Volume 137, Number 6 1403
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risks on short- and long-term outcomes of pneumonectomy.
In 1947 a report by Price Thomas4 on bronchoplasty and in
1986 a report by Vogt-Moykopf5 on arterioplasty showed
their feasibility.
Even though bronchoplasty is accepted and performed in
many centers, PA reconstruction is not. Relatively few
works were published, and this distrust shows that doubts
about surgical technique and morbidity,12 as well as func-
tional and oncologic results, probably still persist.
In our experience and in agreement with others,16,17 arte-
rial resection and reconstruction were performed more fre-
quently for left-sided tumors (72% of patients) and for the
squamous histotype (49.5% of patients). This is obviously
explained by the proximal character of the tumors and the
different anatomy of PAs on the right and left sides, respec-
tively. In most cases PA involvement was partial, and partial
resection and reconstruction (possibly with pericardial
patch) was sufficient to deal radically with the disease,
whereas circumferential resection with an end-to-end anas-
tomosis was carried out in only 3 patients. These data con-
firm previous reports on smaller series dealing with
probably similar patients16,17; comparison with the experi-
ence of Rendina and colleagues18 is not possible because
of different inclusion criteria in their study (only patch re-
construction and circumferential resections were evaluated).
Our figures of perioperative morbidity and mortality
(29.0% and 5.4%, respectively) could seem relatively high,
at least if compared with current figures in standard lobecto-
FIGURE 2. Survival according to peritumoral and intratumoral vascular
emboli in patients with non–small cell lung cancer. The presence of peritu-
moral, intratumoral, or both neoplastic vascular emboli was associated with
significantly (P ¼ .0068) worse 5-year survival (23.6% [95% confidence
interval, 10.6%–44.4%] vs 43.1% [95% confidence interval, 26.7%–
61.2%]).1404 The Journal of Thoracic and Cardiovascular Sumies, but one should consider that patients undergoing arterial
resection have an increased postoperative risk because of lo-
cally more advanced disease. Literature data are quite vari-
able, with values of mortality and morbidity ranging from
0% to 17% and 7% to 40%,11,12,16 respectively, probably re-
flecting the heterogeneity of studied populations and perio-
perative treatments. In our experience no death or major
complications were per se related to the arterial resection
(no major bleeding, pulmonary infarction, or bronchovascu-
lar fistula), although all these complications have been re-
ported in this setting.5,11,17 In agreement with others,16 we
think that careful handling of the vessel and preservation of
a sufficient lumen, together with the use of a pedicled flap, es-
pecially in the case of contact between arterial and bronchial
sutures, are the key measures to eliminate these complica-
tions. Postoperative pneumonia and myocardial infarction
were the leading causes of death, and statistical analysis
showed, as previously reported,19,20 that histories of cardio-
vascular disease (P ¼ .022) and low FEV1 (P ¼ .039) were
independent risk factors of death. In particular, postoperative
pneumonia was responsible for 3 postoperative deaths. In
agreement with other European reports, our team has previ-
ously reported that postoperative pneumonia was a relatively
frequent complication of major lung resection and repre-
sented the leading cause of postoperative death.15 We also
demonstrated that these pneumonias were sustained by germs
responsible for initial (preoperative) bronchial coloniza-
tions.15 More recently, we showed that the adoption of
a new antibioprophylaxis by amoxicillin–clavulanic acid, tar-
geting these germs more specifically than the previously used
second-generation cephalosporin, resulted in a significant de-
crease in postoperative pneumonia.21
On the other hand, in the present series 2 deaths were due
to myocardial infarction. We hope that this complication,
which occurred relatively early in our experience, will be
avoided in the future thanks to the current management of
concomitant coronary artery disease, including, in cases
not susceptible to percutaneous revascularization, the use
of b-blockers and the nondiscontinuation of platelet aggre-
gation inhibitors.
We did not specifically study the late functional status of
our patients or perform late pulmonary angiograms. On the
other hand, all the patients had contrast-enhanced CT scans
6 to 8 weeks postoperatively, and in no case could we detect
a defect of patency of the PA distal to reconstruction, al-
though the accuracy of this evaluation is not absolute.
Relatively few data are available in the literature concern-
ing the long-term outcome of patients treated with arterial
resection and reconstruction.16,22,23 In the recent (2007)
meta-analysis by Ma and colleagues,12 who reviewed recent
studies on parenchymal sparing techniques, 152 patients
from 5 studies were identified. The 5-year survival rate
was 38.7%, a value close to our 34.9%. Obviously these
comparisons are difficult because of differences in termsrgery c June 2009
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niques, and adjuvant treatments. In our experience multivar-
iate analysis showed that the size of the primary tumor and
the presence of vascular emboli were independent factors
of worse outcome, whereas nodal status failed to be identi-
fied as a prognostic factor at either univariate or multivariate
analysis. It is difficult to compare this result with the results
of previous studies because in most series a limited number
of patients treated with angioplastic procedures are often
studied together with patients undergoing simple broncho-
plastic procedures. There are no data on the effect of nodal
involvement on survival in the recent article by Cerfolio
and Bryant,16 and the correlation was not studied in the
above-cited metanalysis.12 In our opinion, as already sug-
gested for other advanced primary tumors,24,25 in this subset
of patients with non–small cell lung cancer, the prognosis
was determined by the tumor itself rather than by the nodal
disease. Furthermore, patients with Nþ disease were more
likely to receive adjuvant or neoadjuvant treatments, with
a probable positive effect on outcome. On the other hand,
in agreement with others,26 we found that the presence of
vascular emboli was an independent negative prognostic
factor explained by the already occurred initial steps of he-
matogenous spreading of the disease.
Our study showed that truly local recurrences were rare
and could be managed with completion pneumonectomy;
this strongly reinforces the idea that arterioplasty with possi-
bly associated bronchoplasty allows one to radically control
the disease. Furthermore, most locoregional recurrences oc-
curred at the mediastinal level and were often associated
with systemic metastases. It is evident that initial pneumo-
nectomy would have not prevented this kind of evolution.
Undoubtedly, the retrospective methodology of the study
and the mix of tumor histology, stage, and preoperative and
postoperative management represent the main limitations of
this study. However, PA resection and reconstruction is, in
our experience, a relatively safe procedure, with acceptable
values of operative morbidity and mortality. Because this
procedure leads to clear margins of resection and spare
lung parenchyma, we recommend, on the basis of our out-
come data, to evaluate its feasibility when possible and
when indicated in an effort to avoid pneumonectomy.
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